Gene therapy: from science to high‑complexity management

Gene therapy is one of the most promising frontiers of contemporary medicine. Its goal is to treat diseases by directly modifying genetic material, acting at the molecular root of the disease.

Unlike more traditional approaches, this strategy offers the possibility of restoring essential cellular functions, enabling clinical results once considered unattainable in several specialties.

What defines gene therapy?

Gene therapy encompasses techniques that introduce, remove or modify genes in human cells for therapeutic purposes. The science behind this innovation uses genetic engineering to give the body the correct information that the genome, for some reason, lacks.

The advances are significant in monogenic diseases, where correcting a single gene can completely transform the patient’s prognosis.

Today, three main strategies underpin this practice:

Gene replacement

Inserting a functional copy of a gene to make up for the absence of a defective original.

Gene editing

Directly correcting specific mutations, using high-precision tools such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats, a natural mechanism found in bacteria that works as a defense system against viruses).

Gene inactivation

Silencing genes that are causing harm to the body.

How is the technology applied in practice?

To get genetic material inside cells, a carrier called a vector is used. Viral vectors are the most common. They take advantage of viruses’ natural ability to invade cells, but are adapted in the lab to be safe and focused exclusively on delivering therapeutic DNA.

Administration takes two main forms:

1. In vivo: the vector is administered directly to the patient, an approach that gains logistical agility.

2. Ex vivo: cells are collected, modified in the lab and reinfused into the patient. An example of the resounding success of this strategy is CAR-T cell therapy, which revolutionized the treatment of blood cancers by “training” the immune system to fight the tumor.

Clinical applications and regulatory approvals

Gene therapy is already a reality in centers of excellence, with protocols approved by agencies such as Anvisa (Brazil), the FDA (US) and the EMA (Europe).

This regulatory validation allows different areas of medicine to already reap the benefits of this technology, notably:

• Rare diseases: conditions such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy and hemophilia have therapies that show a direct impact on survival and quality of life.

• Oncology: treating leukemias and lymphomas through the genetic modification of T lymphocytes is one of the greatest milestones of modern oncology.

• Ophthalmology: diseases such as Leber congenital amaurosis already have treatments that partially restore visual function.

The role of precision diagnostics

Properly indicating gene therapy depends entirely on robust diagnostic medicine. The use of next-generation sequencing (NGS) makes it possible to identify exact mutations, ensuring that the patient receives the right treatment for their specific condition. Molecular diagnosis is what underpins the safety and effectiveness of the entire therapeutic protocol.

Impacts on hospital management and sustainability

Incorporating these therapies requires healthcare institutions to evolve in infrastructure and governance. Because these are high-value interventions, hospital management becomes more efficient by adopting:

• Traceability protocols: ensuring complete safety from cell collection to infusion.

• Outcome-based payment models: innovative agreements with payers in which payment is tied to the patient’s clinical success.

• Data governance: rigorous control of the revenue cycle ensures that high-complexity procedures are properly authorized and billed, avoiding denials and ensuring financial sustainability.

The Rivio view

Adopting innovations such as gene therapy requires operational intelligence that keeps pace with the sophistication of medicine. At Rivio, we understand that managing high complexity requires real-time integration between diagnosis, clinical protocols and contract rules.

Our artificial intelligence works on eligibility validation and documentation compliance, ensuring that every stage of treatment is protected against billing inconsistencies. By connecting care precision with financial security, Rivio’s technology provides the support an institution needs to bring medicine’s frontiers on board with full control and sustainability.